Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma

Area of Science:

• Immunology
• Oncology
• Hematology

Background:

• The bone marrow (BM) microenvironment in multiple myeloma (MM) harbors cellular elements that promote immune evasion, proliferation, and drug resistance.
• Key immunosuppressive components include myeloid-derived suppressor cells (MDSCs), M2-like macrophages, regulatory B-cells (Bregs), and regulatory T-cells (Tregs).
• These cells engage in complex crosstalk, suppressing cytotoxic T-cells and natural killer (NK) cells, thereby facilitating tumor survival.

Purpose of the Study:

• To review the scientific rationale and clinical proof of concept for emerging immunomodulatory therapeutic platforms in multiple myeloma.
• To highlight strategies for overcoming the immunosuppressive tumor microenvironment (TME) in MM.
• To explore new paradigms for improving survival in high-risk and refractory MM patients.

Main Methods:

• Review of existing scientific literature and clinical data on immunomodulatory agents and therapies.
• Analysis of the mechanisms by which different therapeutic platforms target the MM TME.
• Evaluation of combination strategies involving immunomodulatory imide drugs (IMiDs), protease inhibitors (PI), monoclonal antibodies (MoAb), and cell-based therapies.

Main Results:

• Various therapeutic platforms, including IMiDs, PIs, MoAbs, and adoptive cell therapies, demonstrate potential in modulating the MM TME.
• These therapies, when used in combination, can counteract the immunosuppressive effects of cellular elements within the BM.
• Evidence supports the clinical utility of these platforms in managing newly diagnosed and relapsed/refractory MM.

Conclusions:

• Targeting the immunosuppressive TME is a critical strategy for improving MM patient outcomes.
• Combination immunomodulatory therapies offer a promising foundation for a new therapeutic paradigm in MM.
• Further clinical validation is essential to establish these platforms for enhanced survival in high-risk and refractory MM.